Logo

Roche's Hemlibra Receives FDA's Breakthrough Therapy Designation for Hemophilia A without Factor VIII Inhibitors

Share this

Roche's Hemlibra Receives FDA's Breakthrough Therapy Designation for Hemophilia A without Factor VIII Inhibitors

Shots:

  • The FDA’s BT designation is based on P-III HAVEN 3 study assessing Hemlibra vs no prophylaxis in 152 patients in ratio (2:2:1) with hemophilia A + prior treated with factor VIII therapy aged>12years
  • The P-III HAVEN 3 study results: reduction in treated bleeds; superior to prior factor VIII prophylaxis; no thrombotic microangiopathy; no new safety signals observed
  • Hemlibra (emicizumab) IV is a bispecific factor IXa- and factor X-directed Ab- with recommended dose qw- q2w- developed by Chugai and co-developed by Roche and Genentech. In 2017- Hemlibra received the US FDA approval to treat hemophilia A with factor VIII inhibitors in adults and children

Ref: Roche | Image: Roche

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions